Primary pulmonary hypertension is a rare, intractable disease with poor life expectancy, often affecting young females.
May offer therapeutic option in primary pulmonary hypertension; leaves open need for randomized confirmation.
Key words: prostaglanding, pathophysiology, vasodilater Primary pulmonary hypertension (PPH) is a rare but intractable disease entity of unknownetiology (1 , 2). It is seen mainly in young females with symptomsdue to markedly elevated pulmonary arterial impedance, commonlyassociated with severe pulmonary hypertension and low output. The life expectancy after the definite diagnosis is usually within a couple of years
No takes yet. Share an insight, caveat, or question.
Shunnosuke Handa (2002) conducted an editorial in Primary pulmonary hypertension. Prostaglandin derivatives was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: